SCHEMBL13291009

SCHEMBL13291009

Cc1ccc(NC(=O)c2oc3ccncc3c2NC(=O)[C@H]2CC[C@H](C(=O)N(C)CCN(C)C)CC2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ CASP3 P42574 1/20 0.44
▸ SENP7 Q9BQF6 1/20 0.44
▸ SENP6 Q9GZR1 1/20 0.44
▸ MAPT P10636 4/20 0.42
▸ TP53 P04637 2/20 0.42
▸ HSD17B10 Q99714 3/20 0.40
▸ MEN1 O00255 5/20 0.40
▸ ALDH1A1 P00352 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ POLB P06746 3/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ GLA P06280 1/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290977 0.91 SMN1; SMN2 (0.44) KMT2AMAPTTP53HSD17B10MEN1
SCHEMBL13879646 0.90 KMT2A (0.48) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13291010 0.90 MAPT (0.54) KMT2AMAPTTP53HSD17B10MEN1
SCHEMBL13291014 0.85 NPC1 (0.41) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13665087 0.83 NPC1 (0.42) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13290996 0.83 NPC1 (0.39) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13291065 0.82 RAB9A (0.46) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13665070 0.82 NPC1 (0.41) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13664995 0.82 SMN1; SMN2 (0.54) KMT2ANPC1RAB9ACASP3SENP7
SCHEMBL13291003 0.82 NPC1 (0.42) KMT2ANPC1RAB9ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 KMT2A 2033/4885NPC1 4426/4885RAB9A 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback